Rising levels of antimicrobial resistance pose serious dangers to patients, population health, food security, and economic stability worldwide. In response to this threat, the United Nations and the World Health Organization have called for multisectoral, multidisciplinary action, recognizing that human, animal, and environmental health are interdependent. Although the pharmaceutical industry clearly has a leading role in developing novel antimicrobials and vaccines, it is also active in many areas supporting antimicrobial stewardship. This article describes why pharmaceutical companies invest in antimicrobial stewardship, outlines why they are well suited to help address this issue, and provides examples of how the pharmaceutical industry can support the responsible use of antimicrobials. Merck & Co., Inc. (Kenilworth, NJ, USA), a large, globally operating pharmaceutical company that develops and markets both human and veterinary antimicrobials and vaccines is used as a case study for illustrating industry involvement in antimicrobial stewardship efforts.

中文翻译：

---

制药公司在抗菌药物管理中的作用：案例研究。


不断上升的抗菌素耐药性对全球患者、人口健康、粮食安全和经济稳定构成严重威胁。为了应对这一威胁，联合国和世界卫生组织认识到人类、动物和环境健康是相互依存的，呼吁采取多部门、多学科行动。尽管制药行业显然在开发新型抗菌药物和疫苗方面发挥着主导作用，但它在支持抗菌药物管理的许多领域也很活跃。本文介绍了制药公司投资抗菌药物管理的原因，概述了为什么它们非常适合帮助解决这一问题，并提供了制药行业如何支持负责任地使用抗菌药物的示例。默克公司（美国新泽西州凯尼尔沃思）是一家大型全球性制药公司，开发和销售人用和兽用抗菌药物及疫苗，本文将其作为案例研究来说明行业参与抗菌药物管理工作。